Comparison of the prognostic utility of the revised International Prognostic Scoring System and the F rench Prognostic Scoring System in azacitidine‐treated patients with myelodysplastic syndromes
Year: 2014
Type: article
Abstract: The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.
Source: British Journal of Haematology
DOI: 10.1111/bjh.12884
Authors: Amer M. Zeidan, Ju‐Whei Lee, Thomas Prebet, Peter Greenberg, Zhuoxin Sun, Mark Juckett, Mitchell R. Smith, Elisabeth Paietta, Janice Gabrilove, Harry P. Erba, Martin S. Tallman, Steven D. Gore, the Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup
Institutions: Johns Hopkins University, Dana-Farber Cancer Institute, Aix-Marseille Université, Stanford Medicine, Stanford University, University of Wisconsin–Madison, Cleveland Clinic, Montefiore Medical Center, Yeshiva University, Icahn School of Medicine at Mount Sinai, University of Alabama, University of Alabama at Birmingham, Memorial Sloan Kettering Cancer Center, Yale Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G1042980396, ECOG Statistical Office Data Management Grant, G1422427855, ECOG-ACRIN Network Group Operations Center, G2017411191, G2043432835, EASTERN COOPERATIVE ONCOLOGY GROUP, Targeting Epigenomics in Myeloid Neoplasms, G36541222, Eastern Cooperative Oncology Group, SWOG Network Group Operations Center of the NCTN, ECOG Clinical Trials, Southwest Oncology Group, G4412485521, G5765316850, Eastern Cooperative Oncology Group, Southwest Oncology Group Treatment Grant, Cancer and Leukemia Group B, ECOG-ACRIN Network Group Statistics and Data Management Center, G7419356045, ECOG Specimen Banking, EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES, ECOG Statistical Office, Eastern Cooperative Oncology Group Operations Office, Molecular Targets for Cancer Detection and Treatment, Regional Oncology Research Center, G92717670, G964706321, G973482110
OpenAlex ID: W1978358623